Compare Ascendis Pharma A/S (ASND) vs GXO Logistics Inc (GXO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs GXO Logistics Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while GXO Logistics Inc trades at $50.61 (market cap $5.82B). The key difference: Ascendis Pharma A/S is far larger — about 3× GXO Logistics Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| ASND | GXO | |
|---|---|---|
Market Cap | $17.74B | $5.82B |
Sector | Health | Industrials |
52-Week High | $277.18 | $65.59 |
52-Week Low | $163.32 | $45.52 |
Enterprise Value | $18.11B | $10.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GXO Logistics trades at $50.61, down 2.15% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters and holds a low P/S ratio of 0.43. Recent news highlights new partnership renewals and expansion in Europe, supporting growth prospects.
Wall Street analysts are overwhelmingly bullish with an 88.89% buy rating and a $69.33 consensus price target, implying significant upside. Key risks include competitive pressures from Amazon and reliance on retail clients, but improving profit margins and a record sales pipeline provide a positive fundamental outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
